The store will not work correctly when cookies are disabled.
2-[(2,5-Dichloro-benzenesulfonyl)-(4-nitro-benzyl)-amino]-N-hydroxy-acetamide
ID: ALA301786
PubChem CID: 10741470
Max Phase: Preclinical
Molecular Formula: C15H13Cl2N3O6S
Molecular Weight: 434.26
Molecule Type: Small molecule
This compound is available for customization.
Associated Items:
Names and Identifiers
Canonical SMILES: O=C(CN(Cc1ccc([N+](=O)[O-])cc1)S(=O)(=O)c1cc(Cl)ccc1Cl)NO
Standard InChI: InChI=1S/C15H13Cl2N3O6S/c16-11-3-6-13(17)14(7-11)27(25,26)19(9-15(21)18-22)8-10-1-4-12(5-2-10)20(23)24/h1-7,22H,8-9H2,(H,18,21)
Standard InChI Key: MZISFPSOTJFTTJ-UHFFFAOYSA-N
Molfile:
RDKit 2D
27 28 0 0 0 0 0 0 0 0999 V2000
5.7000 -6.8792 0.0000 S 0 0 0 0 0 0 0 0 0 0 0 0
6.2167 -7.1750 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
5.1750 -6.5750 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
7.2625 -4.7625 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
4.6542 -6.8792 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.1292 -6.5750 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
6.2167 -7.7792 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
5.3917 -7.3917 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
6.0042 -6.3542 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
6.7292 -6.8750 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
6.7500 -5.0667 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
7.7917 -5.0667 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
5.1750 -5.9667 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
7.2625 -4.1542 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
3.6042 -6.8792 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
4.1292 -5.9667 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
6.7500 -5.6667 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
6.2167 -4.7625 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
7.2625 -7.1667 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
6.7417 -8.0792 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
5.7000 -5.6667 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
6.7292 -6.2667 0.0000 Cl 0 0 0 0 0 0 0 0 0 0 0 0
7.2625 -7.7792 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
6.2167 -5.9667 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
5.7000 -5.0667 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
6.7417 -8.6875 0.0000 Cl 0 0 0 0 0 0 0 0 0 0 0 0
3.6042 -5.6667 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
2 1 1 0
3 1 1 0
4 11 1 0
5 3 1 0
6 5 1 0
7 2 2 0
8 1 2 0
9 1 2 0
10 2 1 0
11 18 1 0
12 4 1 0
13 3 1 0
14 4 2 0
15 6 2 0
16 6 1 0
17 24 1 0
18 25 2 0
19 10 2 0
20 7 1 0
21 13 1 0
22 10 1 0
23 19 1 0
24 21 2 0
25 21 1 0
26 20 1 0
27 16 1 0
20 23 2 0
17 11 2 0
M CHG 2 4 1 12 -1
M END
Associated Targets(Human)
Molecule Features
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
Drug Indications
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanisms of Action
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Calculated Properties
Molecular Weight: 434.26 | Molecular Weight (Monoisotopic): 432.9902 | AlogP: 2.60 | #Rotatable Bonds: 7 |
Polar Surface Area: 129.85 | Molecular Species: NEUTRAL | HBA: 6 | HBD: 2 |
#RO5 Violations: ┄ | HBA (Lipinski): 9 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): ┄ |
CX Acidic pKa: 8.74 | CX Basic pKa: ┄ | CX LogP: 2.57 | CX LogD: 2.55 |
Aromatic Rings: 2 | Heavy Atoms: 27 | QED Weighted: 0.39 | Np Likeness Score: -2.02 |
References
1. Scozzafava A, Supuran CT.. (2000) Protease inhibitors: synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties., 43 (9): [PMID:10794702] [10.1021/jm990594k] |